close

CRISIL SME Tracker: Strong domestic demand to drive pharma growth in FY23

In December, the domestic pharmaceuticals market grew 10.4 per cent on exceptional growth in both volume sales and prices

Business Standard
A large drug firm has 12-15 therapy divisions, and if each launches a few drugs, the company brings to the market 30-50 brands a year.
Premium

Strong domestic demand and exports to semi-regulated markets are expected to drive revenue growth for the pharmaceuticals sector in the current fiscal year (FY23), though export demand from regulated markets is expected to remain moderate owing to high pricing pressure amid intense competition.
In December, the domestic pharmaceuticals market grew 10.4 per cent on exceptional growth in both volume sales and prices. However, this growth was led by anti-infective therapeutics and could taper in coming months.
 
In this milieu, small and medium enterprises (SMEs), which have a 30-40 per cent share in industry revenue, are expected to grow 7-9 per cent in FY23, compared with 6-8 per cent in FY22. Growth would be led by domestic demand, while exports, which account for about 45 per cent of industry revenue, remain weak. 
Or

Also Read

OEMs to drive 16-18% rise in auto-parts MSME revenues: CRISIL SME Tracker

Punjab & Sind Bank's asset quality deterioration to moderate: CRISIL

Sugar industry MSME margins hit by flat product prices: CRISIL SME TRACKER

Large-panel TVs' share has tripled in 5 years to over 40%: CRISIL report

ITeS sector's growth prospects in FY23 augur well for SMEs: CRISIL

Chatroom: 'Export duty is not part of the price paid or payable for goods'

'DGFT should clarify duty payment for destruction of imported goods'

Sugar industry MSME margins hit by flat product prices: CRISIL SME TRACKER

'Proving identity of re-imported goods essential for claiming exemption'

Chatroom: 'RoDTEP credit doesn't lapse after 1 year from scroll generation'

First Published: Jan 29 2023 | 4:32 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to read more on Business-Standard.com